Cleared Traditional

K142866 - Myoscience iovera system (FDA 510(k) Clearance)

Class II Neurology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K142866 · Myoscience, Inc. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 2015
Decision
112d
Days
Class 2
Risk

K142866 is an FDA 510(k) clearance for the Myoscience iovera system. Classified as Device, Surgical, Cryogenic (product code GXH), Class II - Special Controls.

Submitted by Myoscience, Inc. (Redwood City, US). The FDA issued a Cleared decision on January 21, 2015 after a review of 112 days - within the typical 510(k) review window.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.4250 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Neurology review framework, consistent with the majority of Class II 510(k) submissions.

View all Myoscience, Inc. devices

Submission Details

510(k) Number K142866 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 01, 2014
Decision Date January 21, 2015
Days to Decision 112 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
36d faster than avg
Panel avg: 148d · This submission: 112d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GXH Device, Surgical, Cryogenic
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.4250
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Peers - GXH Device, Surgical, Cryogenic

All 22
Devices cleared under the same product code (GXH) and FDA review panel - the closest regulatory comparables to K142866.
cryoICE cryoXT cryoablation probe (cryoXT)
K250371 · AtriCure, Inc. · Apr 2025
iovera° System
K243677 · Pacira Biosciences, Inc. · Dec 2024
AtriCure cryoICE BOX (ACM)
K243157 · AtriCure, Inc. · Oct 2024
cryoICE cryoSPHERE+ Cryoablation Probe (CRYOSP)
K233170 · AtriCure, Inc. · Oct 2023
iovera System
K220656 · Pacira Biosciences, Inc. · May 2022
Iovera System
K211334 · Pacira Pharmaceuticals, Inc. · Sep 2021